,address1,address2,city,state,zip,country,phone,website,industry,sector,longBusinessSummary,fullTimeEmployees,companyOfficers,auditRisk,boardRisk,compensationRisk,shareHolderRightsRisk,overallRisk,governanceEpochDate,compensationAsOfEpochDate,maxAge,priceHint,previousClose,open,dayLow,dayHigh,regularMarketPreviousClose,regularMarketOpen,regularMarketDayLow,regularMarketDayHigh,payoutRatio,beta,forwardPE,volume,regularMarketVolume,averageVolume,averageVolume10days,averageDailyVolume10Day,bid,ask,bidSize,askSize,marketCap,fiftyTwoWeekLow,fiftyTwoWeekHigh,fiftyDayAverage,twoHundredDayAverage,trailingAnnualDividendRate,trailingAnnualDividendYield,currency,enterpriseValue,profitMargins,floatShares,sharesOutstanding,sharesShort,sharesShortPriorMonth,sharesShortPreviousMonthDate,dateShortInterest,sharesPercentSharesOut,heldPercentInsiders,heldPercentInstitutions,shortRatio,shortPercentOfFloat,bookValue,priceToBook,lastFiscalYearEnd,nextFiscalYearEnd,mostRecentQuarter,netIncomeToCommon,trailingEps,forwardEps,pegRatio,exchange,quoteType,symbol,underlyingSymbol,shortName,longName,firstTradeDateEpochUtc,timeZoneFullName,timeZoneShortName,gmtOffSetMilliseconds,currentPrice,targetHighPrice,targetLowPrice,targetMeanPrice,targetMedianPrice,recommendationMean,recommendationKey,numberOfAnalystOpinions,totalCash,totalCashPerShare,totalDebt,quickRatio,currentRatio,debtToEquity,returnOnAssets,returnOnEquity,freeCashflow,operatingCashflow,grossMargins,ebitdaMargins,operatingMargins,financialCurrency,trailingPegRatio
0,9920 Pacific Heights Boulevard,Suite 350,San Diego,CA,92121,United States,858 704 4660,https://www.vikingtherapeutics.com,Biotechnology,Healthcare,"Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.",22,"{'maxAge': 1, 'name': 'Dr. Brian  Lian Ph.D.', 'age': 56, 'title': 'Pres, CEO & Director', 'yearBorn': 1966, 'fiscalYear': 2022, 'totalPay': 965115, 'exercisedValue': 0, 'unexercisedValue': 5242550}",9,7,8,8,8,1693526400,1672444800,86400,2,15.0,15.03,14.58,15.41,15.0,15.03,14.58,15.41,0.0,0.51556,-14.480392,6216435,6216435,2274633,2189740,2189740,14.65,14.7,1200,800,1477428352,2.535,25.72,14.5967,14.22345,0.0,0.0,USD,1085919744,0.0,94327185,100029000,12912647,11843144,1690761600,1693440000,0.1291,0.058909997,0.68747,8.64,0.1489,3.86,3.826425,1672444800,1703980800,1688083200,-74088000,-0.89,-1.02,-0.42,NCM,EQUITY,VKTX,VKTX,"Viking Therapeutics, Inc.","Viking Therapeutics, Inc.",1430227800,America/New_York,EDT,-14400000,14.77,40.0,28.0,33.8,34.0,1.5,strong_buy,10,392920000,3.928,1414000,29.153,29.631,0.366,-0.17337999,-0.26875,-34759876,-60503000,0.0,0.0,0.0,USD,
1,9920 Pacific Heights Boulevard,Suite 350,San Diego,CA,92121,United States,858 704 4660,https://www.vikingtherapeutics.com,Biotechnology,Healthcare,"Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.",22,"{'maxAge': 1, 'name': 'Mr. Gregory S. Zante', 'age': 51, 'title': 'Chief Financial Officer', 'yearBorn': 1971, 'fiscalYear': 2022, 'totalPay': 603500, 'exercisedValue': 0, 'unexercisedValue': 366013}",9,7,8,8,8,1693526400,1672444800,86400,2,15.0,15.03,14.58,15.41,15.0,15.03,14.58,15.41,0.0,0.51556,-14.480392,6216435,6216435,2274633,2189740,2189740,14.65,14.7,1200,800,1477428352,2.535,25.72,14.5967,14.22345,0.0,0.0,USD,1085919744,0.0,94327185,100029000,12912647,11843144,1690761600,1693440000,0.1291,0.058909997,0.68747,8.64,0.1489,3.86,3.826425,1672444800,1703980800,1688083200,-74088000,-0.89,-1.02,-0.42,NCM,EQUITY,VKTX,VKTX,"Viking Therapeutics, Inc.","Viking Therapeutics, Inc.",1430227800,America/New_York,EDT,-14400000,14.77,40.0,28.0,33.8,34.0,1.5,strong_buy,10,392920000,3.928,1414000,29.153,29.631,0.366,-0.17337999,-0.26875,-34759876,-60503000,0.0,0.0,0.0,USD,
2,9920 Pacific Heights Boulevard,Suite 350,San Diego,CA,92121,United States,858 704 4660,https://www.vikingtherapeutics.com,Biotechnology,Healthcare,"Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.",22,"{'maxAge': 1, 'name': 'Ms. Marianne  Mancini', 'age': 57, 'title': 'Chief Operating Officer', 'yearBorn': 1965, 'fiscalYear': 2022, 'totalPay': 633300, 'exercisedValue': 0, 'unexercisedValue': 1412689}",9,7,8,8,8,1693526400,1672444800,86400,2,15.0,15.03,14.58,15.41,15.0,15.03,14.58,15.41,0.0,0.51556,-14.480392,6216435,6216435,2274633,2189740,2189740,14.65,14.7,1200,800,1477428352,2.535,25.72,14.5967,14.22345,0.0,0.0,USD,1085919744,0.0,94327185,100029000,12912647,11843144,1690761600,1693440000,0.1291,0.058909997,0.68747,8.64,0.1489,3.86,3.826425,1672444800,1703980800,1688083200,-74088000,-0.89,-1.02,-0.42,NCM,EQUITY,VKTX,VKTX,"Viking Therapeutics, Inc.","Viking Therapeutics, Inc.",1430227800,America/New_York,EDT,-14400000,14.77,40.0,28.0,33.8,34.0,1.5,strong_buy,10,392920000,3.928,1414000,29.153,29.631,0.366,-0.17337999,-0.26875,-34759876,-60503000,0.0,0.0,0.0,USD,
3,9920 Pacific Heights Boulevard,Suite 350,San Diego,CA,92121,United States,858 704 4660,https://www.vikingtherapeutics.com,Biotechnology,Healthcare,"Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.",22,"{'maxAge': 1, 'name': 'Mr. Michael  Morneau', 'age': 57, 'title': 'VP of Fin. & Admin.', 'yearBorn': 1965, 'fiscalYear': 2018, 'exercisedValue': 0, 'unexercisedValue': 0}",9,7,8,8,8,1693526400,1672444800,86400,2,15.0,15.03,14.58,15.41,15.0,15.03,14.58,15.41,0.0,0.51556,-14.480392,6216435,6216435,2274633,2189740,2189740,14.65,14.7,1200,800,1477428352,2.535,25.72,14.5967,14.22345,0.0,0.0,USD,1085919744,0.0,94327185,100029000,12912647,11843144,1690761600,1693440000,0.1291,0.058909997,0.68747,8.64,0.1489,3.86,3.826425,1672444800,1703980800,1688083200,-74088000,-0.89,-1.02,-0.42,NCM,EQUITY,VKTX,VKTX,"Viking Therapeutics, Inc.","Viking Therapeutics, Inc.",1430227800,America/New_York,EDT,-14400000,14.77,40.0,28.0,33.8,34.0,1.5,strong_buy,10,392920000,3.928,1414000,29.153,29.631,0.366,-0.17337999,-0.26875,-34759876,-60503000,0.0,0.0,0.0,USD,
4,9920 Pacific Heights Boulevard,Suite 350,San Diego,CA,92121,United States,858 704 4660,https://www.vikingtherapeutics.com,Biotechnology,Healthcare,"Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.",22,"{'maxAge': 1, 'name': 'Dr. Geoffrey E. Barker Ph.D.', 'title': 'Sr. VP of Pharmaceutical Devel.', 'exercisedValue': 0, 'unexercisedValue': 0}",9,7,8,8,8,1693526400,1672444800,86400,2,15.0,15.03,14.58,15.41,15.0,15.03,14.58,15.41,0.0,0.51556,-14.480392,6216435,6216435,2274633,2189740,2189740,14.65,14.7,1200,800,1477428352,2.535,25.72,14.5967,14.22345,0.0,0.0,USD,1085919744,0.0,94327185,100029000,12912647,11843144,1690761600,1693440000,0.1291,0.058909997,0.68747,8.64,0.1489,3.86,3.826425,1672444800,1703980800,1688083200,-74088000,-0.89,-1.02,-0.42,NCM,EQUITY,VKTX,VKTX,"Viking Therapeutics, Inc.","Viking Therapeutics, Inc.",1430227800,America/New_York,EDT,-14400000,14.77,40.0,28.0,33.8,34.0,1.5,strong_buy,10,392920000,3.928,1414000,29.153,29.631,0.366,-0.17337999,-0.26875,-34759876,-60503000,0.0,0.0,0.0,USD,
